Company intelligence / Profile preview
IntelliStem Technologies Inc.
Toronto, Ontario, Canadaintellistemtech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IntelliStem Technologies focuses on developing universal cell-based cancer vaccines using engineered mesenchymal stromal cells with enhanced antigen cross-presentation capabilities. Preclinical results in mice show effective tumor control and synergy with checkpoint inhibitors.
No published human clinical trial results as of the latest update.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cell-based therapies (notably cell vaccines and mesenchymal stromal cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on IntelliStem Technologies Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IntelliStem Technologies Inc..